The subset of patients with acute heart failure able to secrete relaxin-2 at pregnancy concentrations could have a longer survival: a pilot study. (18th August 2018)

• Record Type: Journal Article
• Authors: Miró, Òscar; Herrero-Puente, Pablo; Prieto, Belén; García-García, María; García-Hernández, Pablo; Martín-Sánchez, Francisco J.; Jacob, Javier; Ríos, José; Romero, Rodolfo; Gil, Víctor; Gayat, Étienne; Llorens, Pere; Mebazaa, Alexandre
• Is Part Of: Biomarkers. Volume 23:Number 6(2018)
• Page Start: 573
• Page End: 579
• Publication Date: 2018-08-18
• Subjects: Relaxin-2 -- acute heart failure -- survival -- biomarker -- emergency department; Biochemical markers -- Periodicals; 610.28
• DOI: 10.1080/1354750X.2018.1463564
• Languages: English
• ISSNs: 1354-750X

Abstract

Abstract: Objective: To investigate how many patients with acute heart failure (AHF) hypersecrete relaxin-2 concentrations similar to those of pregnant women and determine their long-term outcome. Methods: In consecutive AHF patients relaxin-2 was quantified by ELISA sandwich method. Patients were divided into pregnancy-like group (PLG, relaxin-2 ≥ 500 pg/mL) and control group (CG, relaxin-2 < 500 pg/mL). The primary outcome was all-cause death during follow-up. Secondary endpoints were prolonged hospitalisation (>10 days), combined endpoint (death, rehospitalisation, ED revisit) 30 days after discharge, and 30-day, one-year and three-year death rates. Results : We included 814 patients [81 (SD = 9) years; 53.0% women] followed during 1.9 (SD 2.8) years; 517 (63.5%) died. Twenty patients (2.5%) formed the PLG (median relaxin-2 = 1459 pg/mL; IQR = 1722) and 794 the CG (median = 26; IQR = 44). There was no interaction with variables included on adjustment (age, sex, ischaemic cardiomyopathy, NT-proBNP, glycaemia, and sodium). PLG patients did not have better short-term secondary endpoints, but did show a significantly lower three-year mortality [ORadjusted = 0.17 (0.05–0.5), p = 0.003]. Conclusions: The small proportion of AHF patients achieving relaxin-2 concentrations similar to those observed in pregnancy may survive longer.